Last update 15 Mar 2025
Tianjin Hongri Jiandakang Medical Technology Co Ltd

Tianjin Hongri Jiandakang Medical Technology Co Ltd

Private Company | Subsidiary Company|
2012|
Tianjin Shi, China
|
www.holyject.com

Overview

Tags

Neoplasms
Respiratory Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms1
Top 5 Drug TypeCount
Small molecule drug1
Top 5 TargetCount
CA2 x CA31

Related

1
Drugs associated with Tianjin Hongri Jiandakang Medical Technology Co Ltd
Para-Toluenesulfonamide
Target
CA2 x CA3
Mechanism
CA2 inhibitors [+1]
Active Org.
Gongwin Biopharm Holdings Co., Ltd.Gongwin Biopharm Holdings Co., Ltd. [+1]
Originator Org.
Tianjin Hongri Jiandakang Medical Technology Co LtdTianjin Hongri Jiandakang Medical Technology Co Ltd
Active Indication
Non-Small Cell Lung Cancer [+1]
Inactive Indication
6-Pyruvoyl-Tetrahydropterin Synthase Deficiency [+5]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date15 Nov 2022
100 Clinical Results associated with Tianjin Hongri Jiandakang Medical Technology Co Ltd
Login to view more data
0 Patents (Medical) associated with Tianjin Hongri Jiandakang Medical Technology Co Ltd
Login to view more data
100 Deals associated with Tianjin Hongri Jiandakang Medical Technology Co Ltd
Login to view more data
100 Translational Medicine associated with Tianjin Hongri Jiandakang Medical Technology Co Ltd
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 29 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Para-Toluenesulfonamide
 ( CA2 x CA3 )		Hepatocellular Carcinoma
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free